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In women facing menopause, end of menstrual activity is accompanied by lower levels of
estrogen and gradual weight gain. Postmenopausal weight gain sounds an alarm for women’s
health and may lead to hyperlipidemia, a lipid increase and glucose intolerance. These
phenomena are connected to lifestyle-related diseases such as hypertension, type II diabetes
mellitus, arteriosclerosis and metabolic syndrome, making it essential to prevent weight gain in
women. A Kampo medicine, Boi-ogi-to, is traditionally used to treat obese conditions, but the
mechanism has not yet been investigated. In this experiment, we tested the antiobesity
properties of Boi-ogi-to in ovariectomized rats by measuring changes of serum cytokine levels
and adipocytokines in fat cells. After treatment with this extract for 6 weeks (20-week-old rats),
we found that there was a significant weight decrease in rats treated with Boi-ogi-to as
compared with that in the control group. Serum tumor necrosis factor (TNF)-a levels increased
significantly in a dose-dependent manner. Gene expression of adipose tissue in uterus also dose
dependently showed a significant increase of TNF-a levels, suggesting that secretion of TNF-a
by fat cells might play a role in the ability of Boi-ogi-to to inhibit weight gain. While
peroxisome proliferators-activated receptor-g and adiponectin levels did not show a significant
difference as compared with those in the control, levels of mRNA expression showed
a tendency to increase dose dependently. Resistin did not show any significant change.
These results suggest that Boi-ogi-to might be useful for the prevention of obesity that occurs
in women with reduction of estrogen.
Keywords: Adipocytokines–Boi-ogi-to–obesity–ovariectomized rats
Introduction
For menopausal women, end of menstrual activity is
accompanied by lower levels of estrogen and gradual
weight gain. This postmenopausal weight gain sounds
an alarm for women’s health (1) since it can lead to
hyperlipidemia, a lipid increase and abnormalities in
blood sugar concentrations. These phenomena are all
connected to lifestyle-related diseases such as hyper-
tension, type II diabetes mellitus, arteriosclerosis and
metabolic syndrome (2,3) making it essential to prevent
weight gain that occurs as the hormone levels are
reduced.
Ovariectomized rats (OVR) are wellknown as a
model for obesity from limited estrogen function (4,5).
The recent report has drawn attention to the connection
of leptin secretion from the lower thalamus with
obesity (6). Other reports have pointed to a connection
between gonadotropins from estrogen and resistin (7).
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properly cited.The decrease in estrogen levels after the removal of
ovaries has been shown to have a direct influence on fat
cells and subsequent obesity (8).
Plants were, and still are, widely used for a number of
conditions affecting women in California. Adams and
Garcia (9) discuss traditional remedies of the Chumash
for dysmenorrhea, premenstrual syndrome, feminine
hygiene, heavy menstruation, urinary tract infections,
parturition, lactation, infant care, menopause, sexually
transmitted diseases, fertility, contraception and abor-
tions. Two Kampo medicines, Bofu-tsusho-san and
Oren-gedoku-to, have revealed an ability to inhibit
weight gain (4,5). Another Kampo medicine, Boi-ogi-to
has been traditionally used to treat obese conditions.
Boi-ogi-to is a component crude herbal drug that con-
tains Sinomenium stem, Astragali radix, Aractylodis
rhizome, Gycyrrhizae radix, Ziniberis rhizome and
Zizyphi fructus. Boi-ogi-to is shown to increase blood
insulin levels and to fall blood glucose concentrations in
streptozotocin-induced, diabetic ddY mice. These actions
are promoted by A. radix included in Boi-ogi-to (10).
This agent has been found to be especially suited to those
with a rounded body type characterized by soft muscles,
water retention, easily tiring and the tendency to have
edema in the lower extremities and knee joints in some
clinical situations.
These characteristics are often found in middle-aged
women and obese children. Since the mechanism for the
efficacy of this component herb has not yet been
discovered, the purpose of our investigation was to
confirm the efficacy of Boi-ogi-to for obesity accompany-
ing menopause. Using a model of OVR, we analyzed
the changes in various cytokines’ levels in the blood
and influence on the adipocytokines of lipid cells in the
uterus.
Materials and Methods
Experimental Animals, Diet and Living Conditions
Ovariectomy was performed for 7-week-old Sprague-
Dawley rats (CLEA, Japan, Inc.) (11,12). After removing
the ovaries, the rats were kept for 7 weeks and were
divided into four groups comprising six rats each to
measure the average weight. The control group (ovx-C)
was fed CE-2 (CLEA Rodent Diet CE-2) from birth until
14 weeks of age. The other three groups received a
mixture of rodent chow and Boi-ogi-to. The ovx-1%
group had 1% Boi-ogi-to mixed in with the rodent chow,
and the ovx-0.5% group included 0.5% Boi-ogi-to
mixed with it, and the ovx-0.25% population did
0.25% Boi-ogi-to.
While undergoing these feeding regimens, weight and
the amount of chow consumed were measured once
a week, at which time the chow was also changed.
The rats were raised at room temperature 231C,
humidity of 555%, circadian cycle was 12h of
darkness, with the light period lasting from 7a.m. to
7p.m., and were fed water and chow ad libitum.
Boi-ogi-to Extract
The component herbal remedy Boi-ogi-to was applied in
this investigation. Clinically, a 1:1 combination ratio of
Shakuyaku and Kanzo is applied based on Shokanron
(Shang han lun: a classic textbook for acute infectious
disease of traditional Chinese medicine). It contains
S. (27.0%), A. radix (27.0%), A. rhizome (16.2%),
G. radix (8.1%), Z. rhizome (5.4%) and Z. fructus
(16.2%). Clinical indications for treatment with this
regent have been as follows: acute to chronic nephritis,
nephritic syndrome, infectious anaphylaxis, cardiac and
renal edema, osteoarthritis, rheumatoid arthritis, neur-
algia and hyperidosis. Since Kampo medicines are made
of natural herbs, the effective components might change,
making it difficult to achieve repeatability in experiments.
To maintain the effective amounts of this extract in
our experiment, we used freeze-dried derivatives of
the Kampo extract (Tsumura Co., Tokyo, Japan). The
quality data regarding a3D, high-performance liquid
chromatography of the constituents are also indicated
in Fig. 1.
Experimental Procedures
The rat weight and dietary consumption were measured
weekly after the age of 10 weeks. Each rat was kept in its
own cage and 3 months after beginning the experiment
(26 weeks of age), the rats were fasted for 24h before
collecting blood samples and blood was taken from their
jugular veins. Two milliliters of blood were taken from
the rat’s jugular vein, 1ml was prepared by centrifugation
and divided into two parts of 500ml each and frozen and
stored at 80C. Afterwards, they were anesthetized with
ether and their abdomens were opened, removing the fat
tissues, the liver, heart and spleen and then weighing
them. Thereafter, we divided the tissues and organs into
thirds, freezing two parts at 80C and fixing one part
in formalin.
Cytokine Measurements
Adiponectin, TNF-a, interferon (INF)-g, interleukin
(IL)-10, IL-6, IL-4, IL-2, IL-1a, IL-1b and granulocyte-
macrophage colony-stimulating factor (GM-CSF) were
measured with a rat cytokine assay according to
the protocol of a suspension array system (Japanese
Bio-Rad Co.)
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Using RNeasy Lipid Tissue Kit (Qiagen Co.), total RNA
was extracted from the fat tissues of uterus. The quality
for RNA was determined by Agilent BioAnalysis. With
the total RNA prepared, expression levels of mRNA of
adiponectin, TNF-a, peroxisome proliferators-activated
receptor (PPAR)-g, or resistin were determined as
follows: Rattus norvegicus adiponectin receptor 1
(LOC289036) mRNA; RA015207-F [CACAGAAAC
TGGCAACATCTGGA]/RA015207-R [CTGAATGAC
AGTAGACGGTGTGGAA], Rattus norvegicus TNF
superfamily member 2 (Tnf) mRNA; RA008379-F [AA
CTCGAGTGACAAGCCCGTAG]/RA008379-R [GTAC
CACCAGTTGGTTGTCTTTGA], Rattus norvegicus
PPAR-gamma (Pparg) mRNA; RA008979-F [TGTCGG
TTTCAGAAGTGCCTTG]/RA008979-R [TTCAGCTG
GTCGATATCACTGGAG], Rattus norvegicus resistin
(Retn) mRNA; RA013938-F [TCATGCCCAGAACCGA
GTTG]/RA013938-R [TCATCCATGGGACACAGTGA
CA]. Modified assay system for these gene expression
analyses (Takara Bio Co.) using real-time polymerase
chain reaction (PCR) was used.
Statistical Analyses
Each measured value was expressed as standard devia-
tions in the average value and significance was deter-
mined by analysis of variance (ANOVA). Using Fisher’s
protected LSD test, a value of P<0.05 was considered
to be significantly different.
Results
Amount of Food Consumed, Body Weight and
Tissue Weights
No significant difference in diet amount was found
among the four groups (ovx-C: 23.70.9g/day, ovx-1%:
22.91.2g/day, ovx-0.5%: 23.51.6g/day, ovx-0.25%:
23.51.3g/day). Changes in body weight during the
observation period are shown in Fig. 2A. As compared
with the control group, the ovx-1% group showed a
significant alteration to lose the weight after the 6th
experimental week (the rats were 20 weeksold). The ovx-
0.5% and ovx-0.25% groups did not change significantly,
suggesting that the concentrations of Boi-ogi-to might
Figure 1. Pattern of 3D, high-performance liquid chromatography of the Boi-ogi-to constituents.
eCAM 2010;7(1) 89influence the tendency towards weight loss. After 3
months (rats were 26 weeks old), the ratios of weight of
the fat tissues of uterus/body weight showed significant
difference according to the concentration of Boi-ogi-to
(Table 1). The ratios of liver weight/body weight and
heart weight/body weight showed significant changes
(Table 1). Figure 2B shows hematoxylin-eosin staining
of adipose cells in the uterus in the control and the
ovx-1% group.
Triglyceride, Cholesterol, Glucose or Insulin in Sera
One and three months after the beginning of experiment
(rats were 18 and 26 weeks old), blood specimens were
taken after the rats had fasted for 24h. The results
regarding serum triglyceride, cholesterol, glucose, or
insulin indicated no significant differences among the
different groups (Fig. 3A–D).
Various Cytokine Levels in Sera
No significant differences in serum adiponectin (Fig. 4A),
INF-g (Table 2), GM-CSF (Table 2), IL-1b (Table 2),
IL-2 (Table 2), IL-4 (Table 2), IL-6 (Fig. 4B) and IL-10
(Table 2) levels were found among the four groups.
However, Fig. 4C shows significant elevation of serum
TNF-a concentrations in a dose-dependent manner in
comparison to that in the ovx-C group. As compared
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Figure 2. Weekly variation of body weight among different groups from the start of treatment with Boi-ogi-to to the end of experiment (A) and
findings of hematoxylin–eosin staining of adipose cells in uterus in the control and the treated group (ovx-1%). (B) Data are expressed as
meansSD. *P<0.05 compared with that in the control. Ovx-1% group had 1% Boi-ogi-to mixed in with the rodent chow, ovx-0.5% group
included 0.5% Boi-ogi-to mixed with it and ovx-0.25% population included 0.25% Boi-ogi-to. The upper and lower images for histopathological
examinations indicate low (100-fold) and high (400-fold) magnifications, respectively.
90 Effects of Bio-ogi-to on obesitywith that in the ovx-C group, the levels of IL-1a were
significantly lower in both the ovx-0.5% and ovx-0.25%
groups (Fig. 4D).
Gene Expression Levels in Fat Tissues of Uterus
Measured by Real-time PCR
Using real-time PCR, we measured expression levels of
the following mRNA in the fat tissues of uterus with
assaying (i) adiponectin, (ii) PPAR-g (iii) resistin and
(iv) TNF-a. The first three parameters showed no
significant changes: (i) adiponectin (Rattus norvegicus
adiponectin receptor 1), (ii) PPAR-g (R. norvegicus
PPAR-g) and (iii) resistin (R. norvegicus resistin). The
TNF-a (R. norvegicus TNF superfamily member 2),
however, showed a tendency to increase dose dependently
as compared with that in the control (Fig. 5A–D).
Discussion
No difference in the diet amount was found among the
different groups, but the body weight of OVR showed
a significant decrease after treatment for 6 weeks. The
possible mechanism of Boi-ogi-to effects on body weight
was not investigated. Regarding the doses of the herbal
drug, the ovx-1% group was administered 56.1mg/kg/
day, ovx-0.5% was 27.1mg/kg/day and the ovx-0.25%
group was 13.0mg/kg/day, showing that weight loss
might be dependent on the administrative doses. In
addition, after 3 months (26-week-old rats) a significant
difference could be found in the ratio of body weight/
weight of fat tissue of uterus. Based on these observa-
tions, we would further propose that Boi-ogi-to might be
useful in regulating weights of fat tissues when estrogen
levels are lowered.
Since there was no change in serum lipids, glucose, or
insulin, insulin resistance was not found after 3 months
of experiment. We did not measure any change of other
lipid profile, such as free fatty acid or HDL and LDL
cholesterol in all groups because we were not able to find
significant difference in serum levels of triglyceride and
total cholesterol.
The cytokine of IL-1 is classified into IL-1 a and IL-1
b based on difference of an isoelectric point. IL-1 is
producted in every organism, and approximately 90%
dose of IL-1 is IL-1 b. IL-1 a is secreted in fibroblast
or keratinocyte whereas IL-1 b is produced in only
phagocyte. However, there is a very limited report on
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Figure 3. Serum levels of triglyceride (A), cholesterol (B), glucose (C) and insulin (D) among different groups at baseline, 1 and 3 months
after treatment with Boi-ogi-to. Data are expressed as meansSD. *P<0.05 compared with that in the control. Ovx-1% group had 1% Boi-ogi-to
mixed in with the rodent chow, ovx-0.5% group included 0.5% Boi-ogi-to mixed with it and ovx-0.25% population included 0.25% Boi-ogi-to.
Table 1. Each ratio of various organ weight per body weight in
different groups
Spleen Liver Heart Adipose tissue
Control 0.1360.014 2.2790.147 0.2390.019 1.9810.129
ovx-1% 0.1540.014 2.1790.15 0.2190.017 1.6820.149*
ovx-0.5% 0.1530.013 2.2510.193 0.240.021 1.5890.166*
ovx-0.25% 0.1330.013 2.2650.193 0.2320.023 1.6070.213*
Data are expressed as means SD. *P<0.05 compared with that in the
control. Ovx-1% group had 1% Boi-ogi-tomixed in with the rodent
chow, ovx-0.5% group included 0.5% Boi-ogi-tomixed with it and ovx-
0.25% population included 0.25% Boi-ogi-to.
eCAM 2010;7(1) 91serum levels of IL-1 a in the environment of obesity
where Boi-ogi-to was administered. In understanding the
meaning of our data regarding the IL-1 a levels, further
investigations about the mechanisms of this cytokine
production are necessary in the future.
Of the serum cytokines’ concentrations, TNF-a levels
showed a dose-dependent increase compared with the
control. The IL-1a levels in the ovx-0.5% and ovx-0.25%
groups, however, showed a significant decrease as
compared with the control. TNF-a is mainly produced
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Figure 4. Serum concentrations of adiponectin (A), IL-6 (B), TNF-a (C) and IL-1a (D) among different groups at baseline, 1 and 3 months after
treatment with Boi-ogi-to. Data are expressed as means  SD. *P<0.05 compared with that in the control. Ovx-1% group had 1% Boi-ogi-to
mixed in with the rodent chow, ovx-0.5% group included 0.5% Boi-ogi-to mixed with it and ovx-0.25% population included 0.25% Boi-ogi-to.
Table 2. Serum levels of various cytokines in different groups
Interferon-g Interleukin-1b
Baseline 1 month 3 months Baseline 1 month 3 months
Control 193.1108.2 701.2770.3 476.8300.3 254.836.8 338.7124.9 258.925.9
ovx-1% 186.1104.1 278.8792.1 405.5252.0 372.738.2 222.3132.2 294.438.0
ovx-0.5% 147.6104.3 210.1152.1 326.463.0 429.628.8 315.8138.5 285.439.8
ovx-0.25% 135.2102.5 483.2150.2 698.459.8 218.327.1 376.589.9 375.646.4*
Interleukin-2 Interleukin-4
Control 3257.59 286.713.4 378.418.8 77.07.97 82.211.3 208.731.3
ovx-1% 330.87.63 272.515.0 408.731.6 76.19.07 95.811.4 244.147.2
ovx-0.5% 345.86.29 311.632.5 425.728.4* 86.810.73 85.714.9 219.847.3
ovx-0.25% 304.78.15 367.434.5* 417.032.4 91.19.74 199.440.13 228.849.1
Interleukin-10 GM-CSF
Control 42.05.50 60.229.4 124.025.0 71.52.48 70.29.02 168.330.3
ovx-1% 42.85.52 45.627.4 158.128.2 70.12.78 73.88.80 219.344.3*
ovx-0.5% 40.74.14 52.423.2 130.324.8 69.56.88 73.810.37 185.937.1
ovx-0.25% 41.82.60 120.116.2 121.130.0 72.66.44 157.320.5 179.438.8
Data are expressed as means SD. *P<0.05 compared with that in the control. The ovx-1% group had 1% Boi-ogi-to mixed in with the
rodent chow, the ovx-0.5% group included 0.5% Boi-ogi-to mixed with it and the ovx-0.25% population included 0.25% Boi-ogi-to. GM-CSF,
granulocyte-macrophage colony-stimulating factor.
92 Effects of Bio-ogi-to on obesityby activating macrophages, and it is in part produced by
the lining cells of blood vessels, adipose cells, microglia
and astrocytes. With obesity, in particular, fat tissues
themselves can take a central role by secreting cytokines
(adipocytokines) (13) with a reaction sensitive to the
metabolism. When lipid cells storing triglycerides are
enlarged, the secretion of TNF-a is increased in the blood
(14). It has been reported that TNF-a production in
fat cells increases the concentration of TNF-a in the
adipose tissues as well as in the blood, and can lead to
improvement of insulin resistance (15). Furthermore,
some reports have shown that TNF-a secreted into the
blood by lipid cells suppresses the activation of tyrosine
kinase through insulin receptors and deteriorates glucose
transport function leading to insulin resistance (16,17),
making it important to confirm the site of TNF-a
production.
In order to clarify the site of TNF-a secretion, we used
an RNA preparation kit for lipids to extract the total
RNA from fatty tissues in the uterus. Our results showed
a significant dose-dependent elevation of TNF-a expres-
sion in the treated groups compared with the control,
leading us to surmise that the ability of Boi-ogi-to to
inhibit weight gain was connected with the secretion of
TNF-a by lipid cells. Although several investigations
(16,17) reported that the secretion of TNF-a into the
blood increases when lipid cells storing triglycerides are
enlarged, the adipose cells were not enlarged and there
were no changes in serum lipids, glucose, or insulin levels
in our investigation, leading us to think that we would
not confirm the advance of insulin resistance. From a
molecular biological standpoint, the rise in TNF-a may
be associated with cell growth since TNF-a is an
inhibitor of cell mitosis (18). It is possible that by
inhibiting the enlargement of lipid cells Boi-ogi-to
facilitates the secretion of TNF-a, an inhibitor of cell
mitosis, and thereby prevents an increase in fatty tissue.
Boi-ogi-to may stimulate lipid cells to secrete TNF-a that
then inhibits cell mitosis. The second possibility is that
TNF-a induces the activation of cyclooxygenase (COX)-2
that then produces prostaglandin (PG) (19). COX-2 is
produced transiently inside the nucleus, and when
inductive enzymes in the nuclear membrane stimulate
the expression of inflammation-related cells, the synthesis
of COX-2 is further enhanced. Important products such
as PGE2 increase the intracellular levels of cAMP and
cAMP can induce COX-2 through positive feedback.
It is possible that the increase in cAMP levels activates
the consumption of energy in lipid cells and inhibits
their enlargement. The third possibility is that Boi-ogi-to
works through the immune system to stimulate lipid cells
to secrete TNF-a and that the measurement occurred
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Figure 5. Gene expression levels of adiponectin (A), PPAR-g (B), resistin (C) and TNF-a (D) in fat tissues of uterus measured by real-time
polymerase chain reaction among different groups at 3 months after treatment with Boi-ogi-to. Data are expressed as meansSD. *P<0.05
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inflammatory cytokines are also produced by activated
macrophages and activated linings of blood vessels, with
a close connection to IL-1, IL-6, INF-g and IL-8. As for
anti-inflammatory cytokines, IL-4, IL-10 and TNF-a are
also concerned with the activated macrophages. In this
experiment, we were unable to deny their connection as a
factor, but there is a possibility that TNF-a is not directly
connected with the inhibition of fat.
There is a limitation in this experiment. We were unable
to clarify the mechanism of Boi-ogi-to action. Compared
with those in the control, PPAR-g and adiponectin levels
in sera did not show significant difference, but the
expression of mRNA showed a dose-dependant tendency
to increase. Resistin levels, however, showed no signifi-
cant change.
Efficacy of Bofu-tsusho-san as well as Boi-ogi-to to
inhibit weight gain has been indicated. Its weight loss
efficacy is derived from activating brown fat tissues
in organs generating heat. The metabolism of whole body
is activated by enhancing the activation of brown fat
tissues in organs generating heat, and then weight loss is
developed. When Yoshida et al. (20) investigated effects
of this drug in an obese mouse model, they showed that
one of the ingredients Ephedra herb of Bofu-tsusho-san
contains ephedrine, which stimulates the sympathetic
nerves. It also contains phosphodiesterase inhibitors,
such as Licorice, Shizonepetae spica and Forsythia,
which degrade fat and activate heat generation in
brown fat tissues, leading to weight loss (1).
Oren-gedoku-to acts on 3T3-L1, precursors of fat cells
to control the specialization of fat cells. Its efficacy is
mainly due to the action of berberine from Coptis
rhizome and Phellodendri cortex that controls the expres-
sion of PPAR-g (2). Berberines have also exhibited
antidiabetic properties in an insulin-resistant animal
model. Furthermore, berberine is related to the genes of
fat formation and becomes involved in the energy
consumption of fat tissues by downregulating or upregu-
lating expression (2). The components of each of these
Kampo medicines differ from those of Boi-ogi-to. Among
the components not found in Boi-ogi-to, Bofu-tsusho-
san contains Ephedra herb, Glycyrrhizae radix, S. spica,
Forsythiae frutcus and Oren-gedoku-to includes C.
rhizome and P. cortex. We could not find a significant
difference in the expression of PPAR-g mRNA among
the different groups. However, we surmised by the
dose-dependent elevation in the mRNA expression that
Boi-ogi-to might have the same mechanism as Oren-
gedoku-to, although a new mechanism would explain its
antiobesity function.
In discussion, we drew a conclusion that TNF-a
partially involved in inhibiting weight gain attributed to
postmenopause by Boi-ogi-to. However, data are weak to
draw such conclusion. More animal experiments and
clinical trials are needed for drawing such conclusion.
Medical approach is now being sought to prevent the
disease onset. Concerning the increasing numbers of
subjects with metabolic syndrome, Boi-ogi-to might
become a strong candidate for use as a preventive
regent. It would be important to further clarify the
pharmacological functions of Kampo medicines (21–24)
as well as Boi-ogi-to. In conclusion, Boi-ogi-to might be
useful to prevent the development of obesity together
with the reduction of estrogen levels.
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